Imetelstat as a Second-line Therapy Option in Low-risk MDS

Imetelstat (IME) has shown promising clinical benefits in patients with lower-risk, transfusion-dependent Myelodysplastic Syndromes (LR-MDS). Across the overall population, treatment with IME demonstrated favorable trends in overall survival (OS), progression-free survival (PFS), and delayed progression to acute myeloid leukemia compared with placebo. Benefits were observed across most patient subgroups, with improvements in OS correlating with both red blood cell transfusion independence and hemoglobin increases. While the study was not specifically powered for statistical significance, these findings reinforce the potential of IME to meaningfully improve clinical outcomes in patients with transfusion-dependent LR-MDS.